Split-face study finds no difference between neurotoxins for glabellar lines
Click Here to Manage Email Alerts
A split-face comparison found no difference between onabotulinumtoxinA and prabotulinumtoxinA for the treatment of glabellar frown lines, according to a study presented at the Women in Ophthalmology Summer Symposium.
“We sought to evaluate the difference in efficacy and safety of onabotulinumtoxinA, an FDA-approved neuromuscular blocking agent that is widely used for cosmetic rejuvenation of the face, and prabotulinumtoxinA, an FDA-approved novel neurotoxin with a similar mechanism of action in treating glabellar lines,” Preeya Mehta, MD, said in her presentation. “At the time of the study, a phase 3 clinical trial had found prabotulinumtoxinA to be noninferior.”
Researchers included 21 patients in a prospective, double-blind, randomized, split-face clinical trial. They injected onabotulinumtoxinA on one side of the glabella and prabotulinumtoxinA on the other. They used the Merz scale to grade photos before and after treatment.
Investigators based the efficacy outcome on change in Merz score from baseline to 3 weeks, as well as scores from patient and provider surveys. They also assessed neurotoxin effect onset and offset.
Mehta and colleagues found no statistical difference in pain, bruising and headaches between the two toxins. Additionally, there was no difference in change in Merz score, or in onset or duration of neurotoxin effect. According to survey results, there was no difference noted by either patients or injectors.
“OnabotulinumtoxinA and prabotulinumtoxinA were both effective in treating glabellar lines at rest and frown when evaluated 3 weeks post-treatment at a total dose of 16 [to] 20 units of neurotoxin,” Mehta said.